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Introduction: The aetiopathogenesis of juvenile dermatomyositis (JDM) remains poorly understood. In particular
the contribution of monocytes or macrophages, which are frequently observed to be an infiltrate within muscle
tissue very early in the disease process, is unknown. We hypothesised that these cells secrete the pro-inflammatory
myeloid related protein (MRP) 8/14 which may then contribute to muscle pathology in JDM.
Methods: In this study of 56 JDM patients, serum MRP8/14 levels were compared with clinical measures of disease
activity. Muscle biopsies taken early in disease were assessed by immunohistochemistry to determine the frequency
and identity of MRP-expressing cells. The effects of MRP stimulation and endoplasmic reticulum (ER) stress on
muscle were tested in vitro. Serum or supernatant levels of cytokines were analyzed by multiplex immunoassay.
Results: Serum MRP8/14 correlated with physician’s global assessment of disease activity in JDM (R = 0.65,
p = 0.0003) and muscle strength/endurance, childhood myositis assessment score (CMAS, R = −0.55, p = 0.004).
MRP8/14 was widely expressed by CD68+ macrophages in JDM muscle tissue. When cultured with human
myoblasts, MRP8 led to the secretion of MCP-1 and IL-6, which was enhanced by ER stress. Both inflammatory
mediators were detected in significantly higher levels in the serum of JDM patients compared to healthy controls.
Conclusions: This study is the first to identify serum MRP8/14 as a potential biomarker for disease activity in JDM.
We propose that tissue infiltrating macrophages secreting MRP8/14 may contribute to myositis, by driving the local
production of cytokines directly from muscle.Introduction
Juvenile dermatomyositis (JDM) is a rare inflammatory
disease of childhood affecting skin and muscle, fre-
quently resulting in calcinosis, and sometimes with po-
tentially life threatening complications including gut
vasculitis and interstitial lung disease [1]. Research into
the disease pathogenesis has identified abnormalities of
the immune system including circulating autoantibodies
targeting nuclear antigens [2], dysregulation of T helper
cell subsets [3] and a prominent interferon alpha (IFNα)
gene signature in the peripheral blood of JDM pa-
tients [4]. In JDM muscle, one of the earliest detectable* Correspondence: l.wedderburn@ucl.ac.uk
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reproduction in any medium, provided the orchanges is increased expression of Class I major his-
tocompatibility complex (MHC) on skeletal muscle [5].
Class I MHC can be upregulated non-specifically in res-
ponse to muscle injury [6], but in JDM is itself thought
to perpetuate the disease process [7]. In animal models,
forced over-expression of Class I protein leads to muscle
fibre damage and a marked myeloid infiltrate into the
muscle [8]. One of the mechanisms of cellular injury,
known as endoplasmic reticulum (ER) stress, results
from accumulation of Class I protein within the ER
which then activates multiple pathways, including the
unfolded protein response (UPR) culminating in muscle
cell death. Gene expression profiling from patients
with adult myositis, as well as animal models, confirm
that the UPR is up-regulated in myositis [7,9]. Despite
clear evidence that ER stress contributes to muscle
cell death, it remains unclear if myocytes directly promoteLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nistala et al. Arthritis Research & Therapy 2013, 15:R131 Page 2 of 11
http://arthritis-research.com/content/15/5/R131the inflammatory process and in particular the mye-
loid cell infiltrate frequently seen early in myositis, or
whether this is merely a secondary response to tissue
necrosis.
Once recruited, myeloid cells may potentiate the loss
of muscle tissue by secreting a potent inflammatory he-
terodimeric protein, myeloid related protein (MRP) 8/14
(S100A8/A9) [10] which signals in a Toll-like receptor
(TLR) 4 dependent manner [11] to induce apoptosis of
skeletal muscle. MRP plays a pathogenic role in other
childhood rheumatic diseases, including arthritis and
vasculitis, and in these conditions it is a valuable bio-
marker of disease severity [12,13]. In JDM, the clinical
and serological markers of skin and muscle disease cur-
rently available lack sensitivity [14]. In this study we ex-
amined the role of MRP8/14 as a biomarker of myositis
and the mechanisms by which MRP8/14 may contribute
to muscle disease. Our results show a close correlation
between MRP8/14 levels in JDM serum and disease
activity scores. MRP8/14 was expressed by CD68+ mac-
rophages within JDM muscle and led to release of in-
flammatory mediators from muscle, an effect that was
accentuated by ER stress. Our study identifies a novel
pathway by which macrophage-muscle crosstalk can per-
petuate inflammatory myositis.
Methods
Patient and control study groups
All patients were recruited to the Juvenile Dermatomyo-
sitis National Cohort Biomarker Study and Repository
for Idiopathic Inflammatory Myopathies (hereafter called
the JDM Cohort study), a UK-wide multicentre cohort
study and biobank for JDM through the UK JDM Re-
search Group (JDRG) [15]. The JDM cohort study had
ethical approval from the North Yorkshire Multi-Centre
Research Ethics Committee and was also approved by
the Steering Committee of the UK JDM Cohort Study. A
total of 56 patients who fulfilled the Bohan and Peter
criteria for definite or probable JDM [16] were included
in this study. Eighteen children (6 boys, 12 girls, mean
age 5.3 years), who had a muscle biopsy taken as part of
the investigation of diverse symptoms, such as clumsi-
ness and falls, were used as controls. As previously re-
ported [17], none of the controls received a diagnosis of
myositis or myopathy and the biopsies were all reviewed
by two expert histopathologists and confirmed to show
normal muscle histology for age and, therefore, consi-
dered to represent suitable control samples. Ethical ap-
proval was obtained from the National Hospital for
Neurology and Neurosurgery and the Institute Of Neu-
rology Joint research ethics committee to use control
muscle biopsies and serum from healthy controls. All
patients (or their carers) provided consent to participate
in the study.Laboratory and clinical measurements
Serum levels of the muscle enzymes lactate dehydroge-
nase (LDH) and creatine kinase (CK) were analysed by
the Great Ormond Street Hospital clinical biochemistry
department. Erythrocyte sedimentation rate (ESR) was
measured by Great Ormond Street Hospital haematol-
ogy department. Standardised outcome variables for the
assessment of JDM, physician determined disease activity
visual analogue score (VAS), childhood health assessment
questionnaire (CHAQ), childhood myositis assessment
score (CMAS) and parental global disease activity VAS
[18,19] were collected prospectively as part of the UK
JDM Cohort Study, as described [15].
Measurement of MRP8/14, MCP-1 and IL-6 concentrations
Serum was extracted within three hours of collection of
peripheral blood and stored at −80°C. Serum concen-
trations of MRP8/14 were determined by sandwich
enzyme-linked immunosorbent assay (ELISA) as previ-
ously described [13]. Monocyte chemoattractant protein-1
(MCP-1) levels were measured in serum using multiplex
immunoassay (Meso Scale Discovery MSD technology,
Meso Scale Diagnostics, USA). MCP-1 was measured in
cell culture supernatants by ELISA (eBioscience, Hatfield,
UK). IL-6, and in some experiments IL-1β, IL-10, IL-17,
TNF-α and IFN-γ, measurements were performed using
multiplex immunoassay [20].
Immunohistochemistry and immunofluorescence staining
Immunohistochemistry and immunofluorescence stain-
ing were performed on biopsies from quadriceps (vastus
lateralis) which were snap frozen within one hour and
stored at −80°C. Staining was performed on acetone
fixed 7 μm cryostat sections. Immunohistochemistry was
performed as described [21] using anti-human monoclo-
nal antibodies to CD68 (KP1), CD3 (UCHT1), MHC
class l heavy chain (W6/32; Novacastra, Milton Keynes,
UK) and MRP8/14 (27E10 [22]). Degree of CD3 and
CD68 infiltration was scored as 0, 1 or 2 as described
[21]: briefly <4 cells in ×20 field scored 0, >4 cells in ×20
and/or 1 cluster scored 1, >20 cells in ×20 and/or >2 clus-
ters in whole biopsy scored 2. For double immunofluo-
rescence staining the following anti-human monoclonal
antibodies were used: CD68 (KP1; Novocastra,), CD14
(TUK4), CD15 (C3D-1; DakoCytomation, Cambridgeshire,
UK), CD163 (RM3/1 [23]) and anti-human polyclonal
MRP14 [10]. Sections were incubated with primary
antibodies at 4°C overnight followed by 30 minutes at
room temperature with secondary antibodies sheep anti-
mouse fluorescein isothiocyanate (FITC) (Sigma, Dorset,
UK) and goat anti-rabbit alexa 568 (Life Technologies,
Paisley, UK). Sections were mounted with Vectashield
mounting medium with diamidino-2-phenylindole (DAPI)
(Vector, Peterborough, UK) and analysed by fluorescent
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markers and MRP14 were counted in ten 10× fields. The
mean percentage MRP14 cells expressing specific lineage
markers were determined.Cell culture and stimulation
LHCNM2, a human skeletal myoblast cell line, was de-
rived from the pectoralis major muscle of a 41-year-old
male Caucasian heart-transplant donor, in accordance
with local ethical legislation [24]. Myoblasts were grown
in (Dulbecco’s) modified Eagle’s medium ((D)MEM)
containing 4.5 mg/ml glucose + MEM 199 (at a ratio of
4:1), supplemented with 20% foetal calf serum (FCS),
100 IU penicillin, 100 μg streptomycin (GIBCO/In-
vitrogen, Paisley, UK). Myoblasts were cultured at 5 ×
104/ml in six-well plates at 37°C in 5% C02 and the
medium was refreshed when cells reached 60% con-
fluence. To test the effects of TLR4 agonists, myo-
blasts were stimulated with lipopolysaccharide (LPS)
or recombinant human MRP8, MRP14 or MRP8/14
[25] or left in culture medium alone. In some experi-
ments myoblasts were pre-incubated for four hours
with thapsigargin, an ER calcium-ATPase inhibitor
which induces ER stress [26]. Thapsigargin was used
at 0.05 μM, LPS at 100 ng/ml and MRP proteins at
5 μg/ml. Supernatants and cells were harvested as a
time course over a 24-hour period. Supernatants were
stored at −80°C for cytokine and chemokine measure-
ments and cells were lysed in TRizol reagent (Invitrogen)
for RNA extraction.Table 1 Summary of patient demographics
JDM patients Median (inter-quartile range)
Age at disease onset 6.0 (3.8 to 9.9) years
Number of male: female patients 14:42
Disease duration 0.5 years (0.25 to 1.8)
CHAQ 1.3 (1.0 to 2.2)
CMAS 33 (14 to 48)
Physician’s Global Assessment 4.2 (2.4 to 7.4)
LDH 1018 (781 to 1759)
CK 223 (56 to 1165)
ESR 19 (13 to 37)
Patients receiving methotrexate 14/48 (29%, 8 missing data)
Patients receiving cortico-steroids 24/51 (47%, 5 missing data)
CK, creatine kinase; CHAQ, childhood health assessment questionnaire; CMAS,
childhood myositis assessment score; ESR, erythrocyte sedimentation rate;
LDH, lactate dehydrogenase.RNA isolation, cDNA synthesis and PCR
RNA from both myoblast cells and muscle tissue was
isolated with TRIzol according to the manufacturer’s in-
structions. cDNA was synthesised using superscript II
RT and random hexamers (Invitrogen). TLR4 expres-
sion on muscle tissue was analysed using Quantitect
TLR4 primers (Qiagen, Crawley, UK). As a read out of
ER stress, expression of x-box binding protein (XBP)-1
splice variants were analysed by PCR using the following
primers: forward CGGAAGCCAAGGGGAATGAA, re-
verse CCCAACAGGATATCAGACTCTGA, at an an-
nealing temperature of 62°C for 35 cycles. Primers to
detect HPRT mRNA (Qiagen) were used as a house-
keeping control for all PCR experiments. PCR products
were visualised by 1.5% agarose gel electrophoresis.
MCP-1 mRNA levels were quantified using real time
PCR, [27] and HPRT gene expression was used for
normalisation. cDNA was amplified using SYBR green
(Bio-Rad Hertfordshire, UK) and thermo cycler rotor-
gene 6000 Corbert (Qiagen). Data were analysed using
Rotor-gene 6000 software (Qiagen).Statistical analysis
Serum MRP levels, muscle enzymes and ESR were com-
pared with clinical measures of disease activity using
Spearman’s Rank. Where parametrically distributed, data
were compared using 1 way or 2 way analysis of variance
(ANOVA) and if appropriate paired t-tests. For non-
parametric results, unpaired data were compared using
the Mann–Whitney test. Differences in CD3/CD68 fre-
quency were analysed by the Chi-Square test for trend.
Results of P <0.05 were considered statistically signi-
ficant. Analyses were carried out in SPSS version 18
(IBM, New York, USA).
Results
Demographics
The JDM patients in this study were representative of
the whole JDM Cohort Study [15] and had evidence of
moderately severe disease activity at the time of sam-
pling with a median CMAS 33, physician’s global assess-
ment 4.2, and CHAQ 1.3 and were analysed early in the
course of their disease (median disease duration six
months, Table 1 and Additional file 1: Table S1).
Disease activity measures in JDM correlate with serum
levels of MRP8/14
Serum levels of the heterodimer MRP8/14 were signifi-
cantly higher in JDM patients compared to age-matched
controls but did not vary according to drug treatment
(Figure 1A, B). Importantly, MRP8/14 levels strongly
correlated with validated clinical measures of disease ac-
tivity (Figure 1B-E), including physician global assess-
ment of disease activity (PGA, R = 0.65, P = 0.0003) and
strength/stamina (CMAS, R = −0.55, P = 0.004), and
only to a limited extent with disability assessment
(CHAQ, R = 0.56, P = 0.062) and the muscle enzyme,
CK (R = 0.4, P = 0.046).
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Figure 1 Disease activity measures in juvenile dermatomyositis (JDM) correlate with serum MRP8/14 levels. (A) Mean MRP8/14
concentrations were measured by ELISA in serum from 32 JDM patients and 32 paediatric controls, * P <0.05. (B) Serum MRP8/14 concentrations
in JDM patients according to treatment status, n = 15 untreated, n = 12 on prednisolone+/−methotrexate, n = 3 methotrexate alone.
(C) Correlation of serum MRP8/14 with physician global assessment (PGA), n = 26, (D) childhood myositis assessment score (CMAS), n = 26,
(E) childhood health assessment questionnaire (CHAQ), n = 12 and (F) creatine kinase (CK), n = 25. Spearman’s Rank was used to assess
correlations between variables.
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muscle
To test if infiltrating myeloid cells in myositis secrete
MRP proteins, biopsies from 46 JDM patients were
stained for MRP14 or the MRP8/14 heterodimer and
compared to muscle biopsies from 14 age-matched con-
trols. In JDM muscle the staining patterns observed sug-
gested that these cells secrete MRP8/14 (Figure 2A, top
right panel). The staining pattern of MRP8/14 in control
samples in contrast was quite distinct (Figure 2A, bot-
tom panel). Thus, control biopsies showed only very
occasional myeloid cells, which although they stainedpositive for MRP8/14, showed no MRP8/14 protein
secretion around the cells. To characterise MRP8/14-se-
creting cells in JDM biopsies, cells were analysed by dual
colour immunofluorescence using polyclonal rabbit anti-
bodies against MRP14 co-stained together with markers
specific for cells of the myeloid lineage CD14, CD15
and CD68 as well as the scavenger receptor CD163
(Figure 2B). By immunohistochemistry, antibody to
MRP14 reliably identified the same cells as those identified
by antibody to MRP8/14 heterodimer (data not shown).
The majority of MRP14 was secreted by CD68 positive
cells (Figure 2B, left hand bar graph). The expression of
Figure 2 CD68 positive myeloid cells in muscle tissue from JDM patients express MRP14 and MRP8/14. (A) Immunohistochemical
staining for CD68 (left) and MRP 8/14 (right) on muscle tissue from JDM patient (top panel) and controls (bottom panel). Positive cells stain
brown as indicated by arrows. Bar represents 50 microns. (B) Two-colour immunofluorescence staining for infiltrating cells, lineage markers
(green), MRP14 (red), double positive cells show as yellow. Bar represents 50 microns. Bar graph illustrates %MRP14+ cells expressing specific
lineage markers, based on counting 10 fields at x10 magnification for each marker, bars and lines represent median and IQR respectively. (C)
Immunohistochemical staining for CD3 and CD68 from JDM patients with a predominant macrophage infiltration, histological score of 0 for T
cells and 2 for monocytes (upper panel), and mixed T cell-macrophage infiltrate, scores 2 for T-cells and 2 for macrophage (lower panel). Bar
represents 100 microns. (D) Percentage of patients with histology scores 0, 1 and 2 for CD68 (macrophage) and CD3 (T cell) frequency in JDM
muscle biopsies (n = 28, Chi square test for trend, P < 0.001). JDM, juvenile dermatomyositis; MRP, myeloid-related protein.
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been described as a marker of anti-inflammatory or ‘alter-
nately activated’ macrophages [28] and the proportion of
CD163+ macrophages in muscle has been shown to
increase after exercise [29]. Double staining in the JDMbiopsies with MRP14 and CD163 showed that the majority
of MRP8/14 secreting myeloid cells within the inflamed
muscle were CD163- (Figure 2B right hand bar graph).
Examining muscle biopsies for myeloid sub-popu-
lations, we frequently observed a heavy infiltration of
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top panels). In contrast biopsies with large numbers of T
cells invariably had a significant macrophage infiltrate
(Figure 2C, bottom panels). This observation raised the
possibility that T cell recruitment could depend on the
early macrophage infiltrate, which establishes the appro-
priate chemokine milieu to attract lymphocytes from the
circulation. To quantify the relative abundance of mac-
rophages and T cells in JDM muscle, we used our biopsy
score tool [21] which includes a semi quantitative assess-
ment of cell infiltration (macrophage infiltration and T
cell infiltration, each scored as 0, 1, or 2). Analysis of
these biopsies (n = 28) showed that muscle sections
scored significantly higher for macrophage infiltration,
than for T cells (P <0.001, Chi square test for trend,
Figure 2D); indeed, 25% of these early biopsies scored 0
for T cell infiltrate. Interestingly, none of the biopsies
assessed had T cell infiltration in the absence of a ma-
crophage population, which suggests that myeloid cellsFigure 3 MRP8 drives production of the chemokine MCP-1 from hum
RT-PCR in human skeletal myoblasts (LHCNM2) and muscle tissue from JDM
(lower panel). (B) MCP-1 and IL-6 production by LHCNM2 cells stimulated f
cultured in medium alone (NS, non stimulated); MCP-1 and IL-6 were meas
respectively; n = 6, bars and lines represent mean and SEM, respectively. Pa
MCP-1 expression (relative units) in quadriceps tissue from JDM patients (n
expression. (D) MCP-1 protein concentration in serum from 14 JDM patien
immunoassay. (E) Serum IL-6 in JDM patients (n = 27) and controls (n = 16
Mann Whitney test was used for unpaired comparisons, *P <0.05, **P <0.00
monocyte chemoattractant protein-1; SEM, standard error of the mean; TLRmay be more important in the early tissue inflammation
of JDM than previously recognised.
MRP8 drives the production of MCP-1 and IL-6 from
inflamed muscle
Myoblasts are known to respond to pathogen associated
molecular patterns (PAMPs), including bacterial LPS, by
secreting inflammatory cytokines and chemokines [30].
Since MRP8 stimulates TLR4, similar to LPS, we hy-
pothesised that tissue macrophages secreting MRP8/14
may propagate leukocyte recruitment in JDM by indu-
cing skeletal muscle-derived cytokines. To test this hy-
pothesis we first confirmed expression of TLR4 on
human skeletal muscle from patients, controls and cul-
tured human myoblasts (Figure 3A). The effects of MRP
homo- and heterodimers on skeletal muscle were tested
by culturing LHCNM2 cells in vitro in the presence of
LPS or MRP proteins. LPS induced high levels of IL-6
and the chemokine MCP-1 from muscle cells, whilstan skeletal muscle. (A) Expression of TLR4 mRNA (upper panel) by
and controls. HPRT mRNA was amplified as a house keeping gene
or 24 hours with 5 μg/ml MRP8, MRP14, MRP8/14 or 100 ng/ml LPS or
ured in cell culture supernatants by ELISA and multiplex immunoassay,
ired t -test was used for comparisons. (C) Quantitative PCR analysis of
= 6) compared to age matched controls (n = 4) normalised to HPRT
ts compared to 16 aged matched controls, measured by multiplex
), measured by multiplex immunoassay. Lines represent medians.
1. JDM, juvenile dermatomyositis; LPS, lipopolysaccharide; MCP-1,
4, Toll-like receptor 4.
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compared to unstimulated controls (Figure 3B). IL-1β,
IL-10, IL-17, TNF-α and IFN-γ were not detected in
muscle supernatants after stimulation. We have pre-
viously shown that MRP8 is the active component in
TLR4 ligation [11]: again in this muscle system, MRP14
and MRP8/14 did not significantly upregulate MCP-1 or
IL-6 from myoblasts. As MRP8 and MRP14 are present
at increased levels in the muscles of JDM patients
(Figure 2A), we asked if this would lead to a correspon-
ding increase in tissue levels of MCP-1. Examining JDM
muscle, we found significantly higher mRNA expression
of MCP-1 when compared to control muscle biopsies (0.3
versus 0.02 relative units, P = 0.0095, Figure 3C). Analysis
of JDM serum also showed significantly higher levels of
MCP-1, as well as IL-6 (Figure 3D and E, respectively),
than samples taken from healthy controls.
XBP-1 and MRP8 interplay in muscle inflammation
Class I MHC over-expression in skeletal muscle
(Figure 4A), which is an early pathological change in
JDM, is known to be associated with ER stress, anFigure 4 Effect of MRP8 stimulation in combination with ER stress on
muscle tissue from JDM patient and age- matched control. Bar represents
24 hours in 0.05 μM thapsigargin (Thaps), mRNA expression of XBP-1 was d
RT-PCR products were analysed on 1.5% agarose gel and stained with ethi
bp XBP-1 transcripts. (C) Mean IL-6 production by LHCNM2 myoblasts follo
following four hours pre-incubation with thapsigargin. Bars represent SEM,
supernatants from LHCNM2 cells cultured with or without thapsigargin, stim
pre-incubation with thapsigargin. Bars and lines represent mean and SEM.
ANOVA, analysis of variance; JDM, juvenile dermatomyositis; LPS, lipopolysa
mean; XBP-1, x-box binding protein 1.established mechanism in the pathogenesis of myositis
[7,9,31]. Recent reports have suggested that XBP-1, a key
transcription factor involved in ER stress [32], may act via
an alternative pathway in monocytes and augment the se-
cretion of TLR induced cytokines [33]. It is, therefore, im-
portant to understand how the interplay between ER
stress and TLR stimulation, in the form of MRP8, would
influence the secretion of inflammatory mediators from
skeletal muscle. LHCNM2 cells were treated with thapsi-
gargin, to induce a stress response which was confirmed
by detecting expression of the active XBP-1 splice product
(26 bp smaller), seen maximally between four to eight
hours (Figure 4B). As previously shown, XBP-1 splicing is
regulated by a negative feedback loop [34], and 16 hours
after exposure to thapsigargin, only the unspliced variant
was detected. To test whether TLR ligation in muscle cells
synergised with ER stress, LHCNM2 cells were cultured
in vitro in the presence of the TLR4 agonist LPS, either
alone or after pre-incubation with thapsigargin. ER stress
clearly synergised with LPS to significantly increase IL-6
secretion from myoblasts when compared to stimulation
with LPS alone (Figure 4C). MRP8, although acting in aIL-6 production by muscle cells. (A) MHC class 1 expression on
50 microns. (B) Human skeletal muscle cells LHCNM2 cultured for 2 to
etermined at indicated times; HPRT mRNA was measured as a control.
dium bromide to visualise spliced (S), 142 bp and un-spliced (US), 168
wing culture in thapsigargin, stimulated with LPS alone or with LPS
data analysed using two-way ANOVA. (D) IL-6 concentration in
ulated with MRP8 or LPS alone, or MRP8 and LPS after four hours
Data analysed by 1 way ANOVA and paired t test *P <0.05, **P <0.001.
ccharide; MRP, myeloid related protein; SEM, standard error of the
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vating downstream signalling cascades, including NF-κB
[11]. Consequently, stimulation with MRP8 resulted in
lower IL-6 levels when compared to LPS (Figure 4D), but
there was still a trend for ER stress to augment the action
of MRP8 (mean IL-6 114.2 pg/ml) when compared to
MRP8 alone (72.8 pg/ml, P = 0.06). ER stress did not
upregulate MCP-1 production following stimulation with
either LPS or MRP8 (data not shown).
Discussion
The assessment of disease activity in JDM, and the dis-
tinction of disease flare from deconditioning or muscle
atrophy, is still largely dependent on clinical evaluation.
In this study, MRP8/14 has been identified as a novel
biomarker of disease activity in JDM, and found to be
superior to existing serological correlates of disease. By
exploring the effects of MRP8 and MRP14 on skeletal
muscle in vitro and correlating results with ex vivo JDM
samples, we have identified a pro-inflammatory role of
MRP8 for myositic muscle that we propose contributes
to the enrichment of key inflammatory mediators MCP-1
and IL-6, seen in JDM muscle and serum, which then con-
tribute to further recruitment of inflammatory cells to
muscle. MRP8 has been shown to be the active compo-
nent stimulating TLR4 in murine models of inflammation
whereas MRP14 seems to have a regulatory function in
the MRP8/14 complex. The exact mechanisms activating
the MRP8/14 heterodimer in vivo are currently not clear
but co-stimulation may be required [35].
MRP8/14 has been shown to be a highly sensitive
marker of disease activity in a range of rheumatic disor-
ders, including arthritis, vasculitis and autoinflammatory
disease [12,13]. As a biomarker, MRP8/14 has many
characteristics that make it suitable for both clinical and
research use; it is easily detected in serum even at low
levels, is already in clinical use to detect gut inflamma-
tion [36] and is stable in clinical serum samples even
when transported at room temperature. Most recently,
we have successfully used MRP8/14 to identify patients
with juvenile arthritis who are likely to remain in remis-
sion following withdrawal of immunosuppression by
methotrexate [37]. This proof of concept study confirms
a role for MRP8/14 in the detection of sub-clinical dis-
ease activity in rheumatic disorders and could poten-
tially apply to JDM to assist with the withdrawal of
immunosuppression.
Other biomarkers have been identified in JDM, in-
cluding the IFNα gene signature and IFN induced che-
mokines [4,38-40]. IFNα is produced by plasmacytoid
dendritic cells (pDC), and induces transcriptional acti-
vators which bind downstream response elements in
promoter sequences (IFN-stimulated response elements,
ISRE), enhancing the transcription of many immunerelated genes including the chemokine MCP-1 [41]. Our
results suggest that MCP-1 can also be produced by a
MRP-dependent pathway, by muscle fibres themselves in
JDM. It is, therefore, of interest, that in a recent report
MCP-1, an IFNα associated chemokine correlated better
with disease activity than the IFNα gene signature itself
[4]. This may suggest that IFNα-independent production
of MCP-1, including muscle derived MCP-1, may play a
role in juvenile myositis.
It is striking that JDM biopsies that were taken re-
latively early in disease (median disease duration six
months), already show a major infiltration of mono-
cytes/macrophages, often in the absence of cells from
the adaptive immune system. Previous studies have not
clearly defined the role of such infiltrating myeloid cells
in muscle cell damage and inflammation during myo-
sitis. Our results clearly show that MRP8 and MRP14
are secreted by CD68+ infiltrating cells and that these
are largely CD163- suggesting that they are indeed pro-
inflammatory in phenotype. We propose that the local
secretion of MRP proteins by these cells has several
downstream effects, including the stimulation of muscle
to produce MCP-1 and IL-6. MCP-1 secreted by skeletal
muscle, in response to MRP, may then play an important
role in propagating the inflammatory infiltrate. Cells
recruited into DM muscle, including monocytes and
memory T cells, express high levels of CCR2, the sole re-
ceptor for MCP-1 [42,43]. MRP8 and MRP14 may be
important in linking an initial innate immune response
with a later adaptive one by recruiting CCR2+ memory
T cells and supporting the differentiation of local B cells
into plasma cells as this is dependent on signalling
through CCR2 [44]. As further evidence of the impor-
tance of MCP-1 in myositis, animal models have impli-
cated this chemokine in a transgenic model of selective
over expression of self MHC Class l in skeletal muscle,
MHC over expression induced MCP-1 production [8]
and, in a model of viral induced myositis, blockade of
MCP-1 significantly attenuated muscle inflammation [45].
Our results demonstrating that MRP8 induced IL-6
and MCP-1 secretion by myoblasts add to a growing
body of evidence that suggests that muscle itself contri-
butes to the inflammatory process [8,46]. To test how
muscle derived cytokine secretion would be altered by
non-immune insults to the muscle, known to occur in
DM [7-9], we adopted a thapsigargin induced model of
muscle ER stress. Using this system we have now identi-
fied ER stress as a mechanism for priming myoblasts to
secrete IL-6 in response to a second signal, such as macro-
phage derived MRP8 binding TLR4. This is pertinent to
myositis as IL-6 is known to correlate with disease activity
in idiopathic inflammatory myositis (IIM) and IL-6 block-
ade attenuates muscle inflammation in some mouse
models [47]. Given that IL-6 is produced by a range of
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difficult to discern the exact contribution made by skeletal
muscle towards the enrichment of this cytokine in JDM
serum. Nevertheless, MCP-1 and IL-6 appear to be tightly
co-regulated in JDM serum [4] and, given that both are
expressed by inflamed muscle, it is possible that the close
correlation between serum levels and muscle disease ac-
tivity [4,40] is explained by the muscle itself being a key
source of these cytokines in JDM.
One limitation of our study is that we are unable to ex-
clude the action of MRP8 on other receptors apart from
TLR4, such as the for advanced glycation end products
(RAGE) [48]. However, data from the murine system would
suggest that TLR4 is the dominant receptor for MRP8 [35].
This study contributes novel insights into the possible
roles of macrophage derived MRP8 and MRP14 in dri-
ving production of chemokines and cytokines by muscle
cells. These data emphasise the importance of skeletal
muscle as an organ with the potential for immune func-
tions and demonstrate how cross talk between muscle
and the innate immune system can be instrumental in
sustaining further adaptive responses as well as on-going
inflammation in autoimmune muscle disease.
Conclusions
Our results highlight the relationship between serum
MRP8/14 levels and disease activity in JDM, and iden-
tify a novel mechanism by which macrophage derived
MRP8/14 may directly activate muscle cells and, thereby,
perpetuate inflammatory myositis. Further prospective
studies are required to test the role of MRP8/14 as a puta-
tive biomarker for disease activity in JDM.
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